Compare NIO Inc. (NIO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs ResMed Inc. — how do they compare? NIO Inc. trades at $3.59 (market cap $8.62B), while ResMed Inc. trades at $230.57 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 3.7× NIO Inc.'s market cap, and ResMed Inc. pays a 1.16% dividend while NIO Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and ResMed Inc. for 51 Days on average.
| NIO | RMD | |
|---|---|---|
Market Cap | $8.62B | $31.89B |
Volume | 39,648,517 | 618,314 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $277.88 |
52-Week Low | $3.37 | $182.82 |
Typical Hold Time | 81 Days | 51 Days |
Enterprise Value | $6.52B | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.60, up 1.69% today but near 52-week lows, with technical indicators showing bearish momentum. The company reported Q3 2026 deliveries up 25.4% and recently completed a strategic battery-swapping partnership with Geely. Despite revenue growth to $87.49B in 2025, NIO continues to post significant losses with a -17.8% net margin. Analyst consensus remains positive with a $6.23 price target, though technical signals and cash flow challenges present headwinds.
NIO's growth trajectory and strategic partnerships offer long-term potential, but investors face substantial execution risks amid persistent losses and competitive pressures. The stock's current discount to analyst targets presents opportunity, but requires careful monitoring of profitability improvements and market share sustainability in the crowded EV sector.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
